A method and a system for quantitative or qualitative determination of a target component in a liquid sample includes i) providing a plurality of magnetic particles including one or more capture sites for the target component on their respective surfaces; ii) providing a plurality of fluorophores configured to bind to the capture sites of the magnetic particles; iii) bringing the liquid sample into contact with the fluorophores and the magnetic particles in a flow channel of a micro fluidic device including a transparent window; and iv) at least temporally immobilizing the magnetic particles adjacent to the transparent window using a magnet, emitting exciting electromagnetic beam towards the immobilized magnetic particles, reading signals emitted from fluorophores captured by the immobilized magnetic particles and performing a quantitative or qualitative determination of the target component based on the read signal.

The present invention provides a fluorescent silica-based nanoparticle that allows for precise detection, characterization, monitoring and treatment of a disease such as cancer. The nanoparticle has a range of diameters including between about 0.1 nm and about 100 nm, between about 0.5 nm and about 50 nm, between about 1 nm and about 25 nm, between about 1 nm and about 15 nm, or between about 1 nm and about 8 nm. The nanoparticle has a fluorescent compound positioned within the nanoparticle, and has greater brightness and fluorescent quantum yield than the free fluorescent compound. The nanoparticle also exhibits high biostability and biocompatibility. To facilitate efficient urinary excretion of the nanoparticle, it may be coated with an organic polymer, such as poly(ethylene glycol) (PEG). The small size of the nanoparticle, the silica base and the organic polymer coating minimizes the toxicity of the nanoparticle when administered in vivo. In order to target a specific cell type, the nanoparticle may further be conjugated to a ligand, which is capable of binding to a cellular component associated with the specific cell type, such as a tumor marker. In one embodiment, a therapeutic agent may be attached to the nanoparticle. To permit the nanoparticle to be detectable by not only optical fluorescence imaging, but also other imaging techniques, such as positron emission tomography (PET), single photon emission computed tomography (SPECT), computerized tomography (CT), bioluminescence imaging, and magnetic resonance imaging (MRI), radionuclides/radiometals or paramagnetic ions may be conjugated to the nanoparticle.

Fluidic devices and methods involving incubation and/or mixing of assay components are provided. In some embodiments, a biological and/or chemical assay may be performed in a fluidic device. The fluidic device may be designed to allow for controlled incubation and/or mixing of two or more assay components. In some such embodiments, the fluidic device may comprise an incubation channel having a relatively large cross-sectional dimension in fluid communication with a detection channel. The incubation channel may allow for adequate mixing and/or incubation of two or more assay components prior to analysis of the assay. In some embodiments, fluidic devices for performing a vitamin D assay are provided.

The present application provides certain advantageous ways of conducting multiplexed imaging.

A surface enhanced Raman scattering device includes a substrate including a substrate surface having a substrate surface energy; a modulation layer formed on the substrate surface and including a modulation layer surface having a modulation layer surface energy; and a surface enhanced Raman scattering structure formed on the modulation layer surface. The modulation layer surface energy is less than the substrate surface energy. A method of manufacturing the surface enhanced Raman scattering device is also provided.

A construct for detecting cellular membrane potential includes a nanoparticle operable as an electron donor; a modular peptide attached to the nanoparticle, the peptide comprising a nanoparticle association domain, a motif configured to mediate peptide insertion into the plasma membrane, and at least one attachment point for an electron acceptor positioned at a controlled distance from the nanoparticle; and an electron acceptor. The nanoparticle can be a quantum dot and the electron acceptor can be C.sub.60 fullerene. Emission correlates with cellular membrane potential.

This invention provides a method for detecting an analyte in a sample, including a step of contacting said analyte with a nanoparticle to facilitate binding thereto, wherein the nanoparticle comprises: (i) a core; (ii) pores extending radially from said core and being defined by spaces between an array of dendritic spikes radiating outwardly from a surface of the core, wherein the pores have an average pore size of between about 10 nm and about 20 nm; (iii) a binding agent for binding the analyte; and (iv) a detection agent immobilized within said pores; to thereby detect said analyte. This invention also provides kits, compositions and products comprising said nanoparticle.

Devices and methods for molecule detection using such devices are disclosed herein. A molecule detection device comprises at least one fluidic channel configured to receive molecules to be detected, a sensor comprising a spin torque oscillator (STO) and encapsulated by a material separating the sensor from the at least one fluidic channel, and detection circuitry coupled to the sensor. At least some of the molecules to be detected are labeled by magnetic nanoparticles (HNPs). A surface of the material provides binding sites for the molecules to be detected. The detection circuitry is configured to detect a frequency or frequency noise of a radio-frequency (RF) signal generated by the STO in response to presence or absence of at least one MNP coupled to one or more binding sites associated with the sensor.

The present invention provides, in a method for measuring a subject substance by using a binding partner that specifically recognizes a substance to be measured, a detection agent for amplifying a signal from a reporter substance that indirectly binds to the substance to be measured via the binding partner, and a signal amplification method using the detection agent. The present invention pertains to the detection agent in which the binding partner which specifically recognizes a substance to be measured is immobilized on gold nanoparticles together with a plurality of the reporter substances.

An analysis device for an objective biological substance includes a generator, a divider, an analyzer, and a calculator. The generator generates a microscopic image of a tissue sample after staining. The divider divides the microscopic image into at least one section having a prescribed size. The analyzer analyzes a staining condition of the microscopic image for each section. The calculator calculates a prescribed statistic based on an analysis result by the analyzer.